Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Healthy Volunteers
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Factorial AssignmentIntervention Model Description: Part A is a randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study with 3 planned cohorts. Part B consists of two randomized, open-label, two-sequence, two-period crossover cohorts comparing the new niclosamide solution with the marketed chewing tablets. Part C is a randomized, double-blinded, placebo-controlled multiple dose study investigating the safety and pharmacokinetics of the combination of niclosamide solution and camostat over a treatment period of 7 days.Masking: Double (Participant, Investigator)Masking Description: This three part study has double-blinded (placebo-controlled) and open-label parts.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 45 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04644705
- Collaborators
- Bayer
- Investigators
- Principal Investigator: Maximilian Posch, Dr. med. Charité Research Organisation GmbH
Get Well Soon